GlaxoSmithKline Pakistan Limited (PSX: GLAXO)

Market Cap	132.76B
Revenue (ttm)	56.23B
Net Income (ttm)	4.51B
Shares Out	318.47M
EPS (ttm)	14.15
PE Ratio	29.46
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	614,327
Average Volume	433,191
Open	414.00
Previous Close	413.31
Day's Range	411.00 - 427.00
52-Week Range	77.00 - 444.00
Beta	0.26
RSI	58.35
Earnings Date	Feb 28, 2025

About GlaxoSmithKline Pakistan

GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan and internationally. It deals in anti-infective, dermatology, respiratory, analgesics, immunology, oncology, urology, HIV, vaccines, and analgesics therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Cutivate, Calpol, Boostrix, Rotarix, Havrix, and Synflorix. The company was founded in 2001 and is headquartered in Karachi, Pakistan. GlaxoSmithKline Pakistan Limited is a subsidiary of GSK plc.

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 2001
• Employees: 1,700
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: GLAXO

Financial Performance

In 2023, GlaxoSmithKline Pakistan's revenue was 49.66 billion, an increase of 18.69% compared to the previous year's 41.84 billion. Earnings were 533.95 million, a decrease of -78.32%.